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Incidences of infections due to Candida have
increased over the last 15±20 y. This increase in the
incidence and the high associated mortality rate
despite therapy has focused the attention on this
disease and prompted investigators to undertake
research aimed at understanding the pathogenesis of
this disease as well as methods to treat it. This paper
discusses recent developments in the Candida ®eld
and the impact they have on patient management.
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merging infectious diseases are diseases of infectious
origin whose incidence in humans has increased within
the past two decades or whose incidence threatens to
increase in the near future. In this regard, Candida is
among those diseases whose incidence has increased
over the past 15±20 y. Wey et al (1998) provided the ®rst evidence
that fungi had begun preying on the growing population of patients
with impaired immune systems (e.g., AIDS, cancer patients). In
their study, these authors showed that nearly 40% of all deaths from
hospital-acquired infections were not due to bacteria or viruses, but
to fungi, with the main culprit being Candida. Supporting evidence
for the increase in the incidence of candidal infections could be
derived from various databases, including the National Hospital
Discharge Survey (NHDS), the Professional Activity Survey (PAS),
and the McDonnell Douglas Automation Company Medical
Records System (McAuto), which showed that in the 1980s the
incidence of candidiasis in hospitalized patients has increased from
<0.5 to about 2 per 1000 hospitalized admission (Fisher-Hoch and
Hutwagner, 1995). Interestingly, age-speci®c rates of oropharyn-
geal candidiasis derived from NHDS data demonstrated clearly that
the increase in this incidence was true irrespective of the age group
(Fisher-Hoch and Hutwagner, 1995). Follow-up surveillance
studies conducted in the 1990s demonstrated that the high
incidence of candidal infections in hospitalized patients is still true.
Edmond et al (1999) undertook a survey referred to as Scope
Project (Surveillance and Control of Pathogens of Epidemiologic
Importance) where they conducted concurrent surveillance for
bloodstream infections at 49 hospitals over a 3 y period. In this
study, more than 10 000 Gram-positive, Gram-negative, and yeast
infections were monitored. Data analyzes showed that whereas
Gram-positive and Gram-negative bacteria accounted for 64% and
27% of cases, respectively, yeast accounted for 8% of cases.
Furthermore, Enterobacteria, Serratia, and coagulase (±) staphylococci
and Candida were more likely to cause infection in the critical care
setting. This study shows that Candida continues to be an important
cause of nosocomial bloodstream infection. Importantly, similar to
earlier ®ndings, yeasts were associated with the highest crude
mortality (40%). Unlike the situation with candidal bloodstream
infections, which remain high, the incidence of esophageal
candidiasis in the HIV/AIDS setting has decreased. This decrease
could be attributed to the host immune reconstitution brought
about by the new antiretroviral therapy (Highly Active
Antiretroviral Therapy, HAART). The decrease in esophageal
candidiasis in both adults and children is documented in the study
of Kaplan et al (2000), who investigated the epidemiology of HIV-
associated opportunistic infections (OI) in the U.S.A. in the era of
HAART (Kaplan et al 2000). These authors showed that, among
other OI, the incidence of esophageal candidiasis has dropped
signi®cantly between 1996 and 1997; however, a disturbing trend is
seen between 1997 and 1998, where the incidence of esophageal
candidiasis seems to be on the incline again. This observation
indicates that it is prudent to continue following the epidemiology
of this and other opportunistic infections, and that it is too early to
draw ®rm conclusions regarding such trends. The decrease in the
incidence of OI, including candidiasis, has been attributed to the
restoration of speci®c immunity (Kelleher et al, 1996; Autran et al,
1997; Pakker et al, 1997; Angel et al, 1998); however, protease
inhibitors could also be exerting a direct effect on C. albicans
secretory aspartyl proteases (Sap), which have been shown to be
virulence factors for C. albicans (Hube, 1996). In this regard,
Cassone et al showed that the protease inhibitors indinavir and
ritonavir inhibited Sap activity and production (Cassone et al,
1999). Further studies are required to demonstrate whether Sap
inhibition is implicated in the decrease of candidiasis in AIDS
patients. It is critical to clarify that the observation that the
incidence of OI, including candidiasis, is decreasing in the HIV-
infected patients is limited to developed countries (mainly the
U.S.A. and Western Europe). The incidence of these devastating
diseases is still high in developing countries, however, particularly
sub-Saharan Africa where between 20% and 50% (depending on
the country or regions within a country) of the population are
infected with this virus (Schooley, 2000).
The increase in the incidence of serious candidiasis and the high
associated mortality rate, even with therapy (35%±50%), has focussed
the attention on this disease and prompted investigations aimed at
improving our understanding of the pathogenesis of this disease, and
host±parasite interactions (Pittet et al, 1994). This paper will focus on
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recent developments in the Candida ®eld that impact patient
management.
RISK FACTORS AND CANDIDA SPECIES
Candidiasis is an infection of the immunocompromised. This
implies that for Candida to cause an infection, one or more risk
factors should be present. A number of factors have been suggested,
including underlying immune insuf®ciency, use of broad-spectrum
antibiotics, cytotoxic agents (e.g., anticancer agents), immunosup-
pressive drugs, and central venous catheters.
Although a number of Candida species exist, only 10 species have
been associated with infection to any signi®cant degree. These
include: C. albicans, C. tropicalis, C. glabrata, C. krusei, C. lusitaniae,
C. parapsilosis, C. guilliermondii, C. pseudotropicalis, C. rugosa, and
C. stellatoidea. For a long time (up to early 1990s), C. albicans was
the main etiologic agent of candidiasis, responsible for more than
70% of all Candida infections. With the introduction of the azoles
(late 1980s, early 1990s), a shift in the candidal species causing
infection started to occur with non-albicans becoming more
important in the disease process. This point is clearly shown in
the Edmond et al study that reported that the non-albicans species
caused between 30% and 54% of the yeast infection (Edmond et al,
1999). Moreover, these authors showed that the extent of yeast
infections caused by non-albicans Candida varied with the
geographic region. According to their study, the north-east region
of the U.S.A. had the highest percentage (54%) of nosocomial
bloodstream infections due to non-albicans species, and the south-
west had the least (30%). Candida glabrata and C. tropicalis were the
second and third causative Candida, after C. albicans, respectively
(Edmond et al, 1999). This change in the pattern of candidal species
causing infections impacts the management of this disease. For
example, C. glabrata tends to have higher minimum inhibitory
concentrations (MIC) values to the currently used antifungals,
particularly the azoles (MIC 16±32 mg per ml). Moreover,
infections caused by this species are associated with poor prognosis
(Nguyen et al, 1996). Thus, the use of high doses of ¯uconazole
(800 mg daily) is recommended for the management of candidiasis
caused by C. glabrata.
DIAGNOSIS
Currently, bedside evaluation, blood cultures, diagnostic imaging,
and biopsies are standard clinical and laboratory tools used in the
diagnosis of invasive candidiasis. Unfortunately, these methods lack
sensitivity in the early recognition of this infection and are
imprecise as markers of complete eradication of infection. Many of
the early attempts of nonculture diagnosis of invasive candidiasis
lack sensitivity; however, advances in the identi®cation and
puri®cation of potential antigens, monoclonal antibody production,
epitope mapping, recombinant DNA techniques, and polymerase
chain reaction (PCR) should contribute towards further develop-
ment of diagnostic methods for fungi that are increased in both
sensitivity and speci®city. As these studies have been extensively
reviewed (Jones, 1990; Walsh et al, 1991; de Repentigny, 1992;
Reiss and Morrison, 1993; Verweij et al, 1998), a brief description
of the current status of research will be provided in this proposal.
Culture-based methods Detection of Candida spp. in the
bloodstream is a key factor for establishing a diagnosis of invasive
candidiasis. There have been numerous advances in blood culture
methodology over the past 10±15 y that have contributed to
improved detection of candidemia (Bougnoux et al, 1990; Kohno et
al, 1993; Chen et al, 1997). Presently the lysis centrifugation and
Bactec methods are the most superior of the systems developed.
Although these methods are clearly a technologic advance these
systems have a low sensitivity in the early detection of candidemia
(between 25% and 82%) (Jones, 1990). Additionally, analysis of the
available data indicates that maximum detection of fungemia is
achieved when more than one blood culture system is employed
(Pfaller and Wenzel, 1992). The length of time (minimum of 5 d)
needed to recover Candida is another limitation with blood culture
methods. These drawbacks emphasize the need for innovative
nonculture methods that allow early detection of candidiasis, and/
or complement blood culture.
Non-culture methods Molecular and biochemical factors
involved in Candida infections have been investigated to develop
nonculture diagnostic methods. These factors include (i) Candida
antigens, (ii) antibodies against Candida antigens, (iii) Candida
metabolites, and (iv) Candida DNA sequences.
Detection of Candida antigens Several workers attempted to
develop immunoassays for detecting C. albicans antigens in sera
from infected patients (Bennet, 1987; Jones, 1990; de Repentigny,
1992; Reiss and Morrison, 1993). These investigators employed
radioimmunoassay (RIA), enzyme-linked immunoassay (ELISA),
and latex agglutination to identify circulating and/or cytoplasmic
antigens.
Cell-wall mannans The cell wall mannan (mannoprotein) of
Candida has been studied extensively at the immunologic level.
Thus, mannan extracts of varying degrees of purity have been used
for serodiagnosis (Odds, 1988). Cell wall mannan antigen is not
usually detectable unless the immune and other circulating
complexes are disrupted by hydrolysis (Walsh et al, 1995).
Another limitation to using mannan is that it is cleared rapidly
from the serum (i.e., transient). Consequently, repeated serum
sampling is necessary (Jones, 1990; de Repentigny, 1992). In spite
of these limitations a number of commercial tests are available in
Europe for mannan detection. Unfortunately the sensitivity of these
tests is still a drawback (Fujita and Hashimoto, 1992).
Enolase Candida enolase, a 48 kDa cytoplasmic antigen, is
recognized by human sera, and is associated with invasive
candidiasis (Strockbine et al, 1984). A multicenter study of high-
risk cancer patients with invasive candidiasis showed that the
enolase-based method has a 54% sensitivity (Walsh et al, 1991).
Multiple serum sampling improved sensitivity (up to 75%) and
speci®city (up to 96%). Although enolase showed a lot of initial
promise, developing a commercial assay was not cost effective
(Sendid et al, 1999). Furthermore, the need for multiple sampling to
improve sensitivity indicates that enolase-based diagnostic assay can
complement but not replace blood cultures in the diagnosis of
invasive candidiasis (Walsh et al, 1991).
Detection of circulating antibodies Anti-Candida antibodies
have been investigated as diagnostic markers of invasive candidiasis
(Taschdjian et al, 1973; Kozinn et al, 1978; van Deventer et al,
1996). Anti-Candida-enolase antibody was detected in sera of less
severely immunocompromised patients with invasive candidiasis
(Walsh et al, 1991). Furthermore, antimannan antibody was
detected in patients with mycologically and clinically proven
candidiasis (Sendid et al, 1999). Unfortunately, the low, sometimes
undetectable, levels of certain antibodies in immunocompromised
patients limit their reliability as diagnostic markers.
Detection of Candida metabolites
D-arabinitol D-arabinitol, a sugar alcohol metabolite from
C. albicans, has been used as a marker for invasive candidiasis
(Christensson et al, 1997). D-arabinitol is cleared by glomerular
®ltration in the body. Thus, impaired renal function may lead to
elevated serum concentrations of D-arabinitol, which can be
detected by gas-liquid chromatography (GLC) or by mass
spectroscopy (MS) with selected ion monitoring. Elevated levels
of D-arabinitol are observed in cases of invasive candidiasis, but not
in infections due to C. glabrata and C. krusei (Lehtonen et al, 1996).
Although elevated levels of D-arabinitol are speci®c to invasive
candidiasis, the amount of time and cost involved and also the
complexities of GLC and MS discourage the use of this method as a
routine diagnostic tool (McSharry et al, 1993). Nonetheless, an
enzymatic-¯uorometric method for determination of serum
D-arabinitol has been developed using Klebsiella pneumoniae
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D-arabinitol dehydrogenase that oxidizes D-arabinitol (Walsh et al,
1994). The utility of D-arabinitol is still under investigation.
1,3-b-D-glucan 1,3-b-D-glucan is a major structural component
of the fungal cell wall that is released by several pathogenic fungi
including C. albicans. Detection of 1,3-b-D-glucan is based on the
coagulation system in the Limulus amoebocyte (Ikegami et al, 1988;
Obayashi et al, 1995). Although 1,3-b-D-glucan has been detected
in plasma from patients with systemic mycoses, concentration of
this component was signi®cantly higher in those with invasive
candidiasis. Thus, this assay may have some clinical utility for
diagnosis of invasive candidiasis; however, this approach is still
under investigation.
Ampli®cation of Candida DNA by PCR Several laboratories
are actively pursuing the development of PCR-based tests for rapid
diagnosis of invasive candidiasis. These assays have focussed on the
use of universal fungal primers, multicopy gene targets, and species-
speci®c DNA regions (Reiss et al, 1998). The universal fungal
oligonucleotide primer pair ITS86 and ITS4, which are designed
based on the conserved sequences of the 5.8S and 28S ribosomal
DNA, respectively, ampli®es a species-speci®c internal transcribed
spacer, ITS2 region (Lott et al, 1998). The variability in length of
this region between different fungal species is the basis for diagnosis.
Similarly, sequences from the fungal lanosterol 14a-demethylase
gene have been used in a PCR approach to develop a diagnostic
test for invasive candidiasis (Buchman et al, 1990; Morace et al,
1999). The family of secreted aspartic proteinase genes has also been
the focus of PCR ampli®cation (Flahaut et al, 1998).
The use of PCR as a diagnostic technique for fungal infections
has gained favor because it is rapid, sensitive, and speci®c; however,
the high sensitivity can in fact be a potential disadvantage because
detection of commensal C. albicans strains, in otherwise uninfected
individuals, may produce false positive reactions (Flahaut et al,
1998). Likewise DNA sequences from dead or degrading fungal
cells may also be ampli®ed.
Taken together, although extensive attempts at developing
methods to diagnose fungal infections, including Candida, are
currently being pursued, all of these methods are still investiga-
tional, making conclusions regarding their ef®ciency premature. To
date, the contributions of antibody or antigen detection tests
remain unsatisfactory. Studies using PCR to detect candidiasis in
neutropenic patients have shown some promise; however, clinical
trials are needed to evaluate their utility.
ANTIFUNGAL SUSCEPTIBILITY TESTING AND
RESISTANCE
The development of standardized antifungal susceptibility testing
procedures was spearheaded by the National Committee for
Clinical Laboratory Standards (NCCLS), Subcommittee for
Antifungal Susceptibility Testing. This development passed
through a number of phases:
(i) Examination of the role of variables such as inoculum prepar-
ation, inoculum size, medium composition, incubation tempera-
ture, incubation time, and endpoint de®nition on interlaboratory
variability (Guinet et al, 1988; Pfaller et al, 1988, 1990; Espinel-
Ingroff et al, 1991, 1992; Shawar et al, 1992; Fromtling et al, 1993;
Troillet et al, 1993; Barchiesi et al, 1995; Ghannoum et al, 1996).1
(ii) Publication of the NCCLS document M27-p (proposed),
which set the initial conditions for the standardized method: a
macrobroth methodology using a starting yeast inoculum of 0.5±
2.5 3 103 cells per ml, RPMI-1640 medium buffered to pH 7.0,
incubation for 48 h (Candida species) or 72 h (Cryptococcus
neoformans) at 35°C and carefully de®ned endpoint criteria.
(iii) Revision and publication of the M27-T as a tentative standard.
The main changes in this version included a microdilution format
for the standard method, modi®cations on determining the
susceptibility testing of C. neoformans, and determining the
susceptibility of Candida against amphotericin B. The second
addition to the M27-T document addressed the dif®culty inherent
in determining the susceptibility of yeast to amphotericin B using
RPMI-1640. This medium tends to cluster the MIC values in a
very narrow range, making it dif®cult to differentiate between
resistant and susceptible isolates (Ghannoum et al, 1992; Rex et al,
1995).
(iv) Revision and publication of M27-A (approved) (National
Committee for Clinical Laboratory Standards, 1997). This repre-
sents the ®nal stage in the development of the standardized method
for antifungal susceptibility methodology for yeast. The main
modi®cation introduced in this document is the development of
breakpoints for antifungal susceptibility testing (see below for
details).
Now that an approved version of M27 is published, it is
important to stress that the process of developing standardized
susceptibility testing for fungi is a dynamic process; and a number of
studies are currently underway to make the yeast method more
amenable for routine clinical use (Rex et al, 1995; Tiballi et al,
1995; Hawser et al, 1998; Lozano-Chiu et al, 1998). Moreover, a
number of investigations are currently underway to develop
optimal methods for determining the antifungal susceptibility
testing of dermatophytic fungi. Although this topic is beyond the
scope of this review, interested readers should consult Norris et al
(1999) and Jessup et al (2000a).
Clinical utility of the antifungal susceptibility testing
method For a susceptibility testing method to be clinically
useful, it should have the ability to predict clinical outcome. A
number of studies were performed to test whether antifungal
susceptibility testing methods, including NCCLS M27, can be used
to predict outcome. These investigations have been previously
reviewed and will not be presented here in detail (see Ghannoum et
al, 1996; Reyes and Ghannoum 2000). Brie¯y, these reports show
that the largest number of studies correlating in vitro antifungal
susceptibility testing with clinical outcome involve ¯uconazole, and
focus on oropharyngeal candidiasis in patients with AIDS
(Horsburgh and Kirkpatrick, 1983; Merz, 1984; Wingard et al,
1991; Ghannoum et al, 1992; Reynes et al, 1992; Bart-Delabesse
et al, 1993; Pfaller et al, 1994; Sangeorzan et al, 1994; Ghannoum,
1996).2
To determine whether or not a correlation exists between MIC
data and clinical outcome, the NCCLS Subcommittee for
Antifungal Susceptibility Testing reviewed data on ¯uconazole
and itraconazole, provided by P®zer Pharmaceuticals and Janssen
Pharmaceuticals, respectively, and proposed tentative breakpoints
for MIC for these drugs as determined by the NCCLS M27
macrobroth methodology. Analysis of these data showed strong
correlation between MIC and clinical outcome. For ¯uconazole
patients on a dose of 100 mg per day, the success rate was >95% up
to an MIC of 8 mg per ml. Conversely, the success rate for isolates
with MIC > 16 mg per ml was lower with an overall success rate of
76%. The correlation between MIC data and clinical correlation
becomes even more obvious when we consider isolates obtained
from patients treated with more than 100 mg per day of
¯uconazole. The success rate in this group is strikingly uniform at
80%±90% for all isolates with MIC < 32 mg per ml. A signi®cant
decrease in the success rate is, however, noted for the isolates with
MIC of 64 mg per ml and greater (46% success rate). Thus the data
support the concept that response to ¯uconazole is a function of
both MIC and drug dose.
Since 98% of candidal strains used for analysis of in vitro±in vivo
correlation in patients treated with itraconazole were obtained from
1Troke PF: Fluconazole Susceptibility Testing Group. Standardized
susceptibility testing of ¯uconazole: a nine centre, international collabora-
tive study. In: Abstract 32nd Interscience Conf Antimicrob Agents Chemother.
Washington, DC: American Society for Microbiology, 1992, Abstract 1596
2Ganger G, Just-Nubling G, Eichel M, Hoika R, Stille W, Goethe J:
Itraconazole solution in patients with non-response to ¯uconazole. In:
Abstract 9th Int Conf on AIDS. Berlin: International AIDS Society, PO-
B09-1394, 1993
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individuals treated with a 200 mg per day dose, dosage was not
considered in the analysis; however, itraconazole plasma levels were
available for many of the patients. Furthermore, data in the
literature indicate that patients with AIDS who are infected with
candidal isolates and who have decreased susceptibility to
¯uconazole, may respond to higher doses of itraconazole
(Fromtling et al, 1993; Warnock et al, 1999). Therefore, the
committee decided to include plasma levels in the analysis.
Examination of the data shows that the success rate of itraconazole
is > 81% for those patients infected with isolates with an MIC of
< 0.125 mg per ml and the outcome appears to be independent of
drug plasma levels. Among patients with itraconazole plasma levels
< 5 mg per ml, the success rates decrease for those individuals
infected with isolates inhibited by 0.25±0.5 mg per ml and > 1.0 mg
per ml (50% and 44% success rates, respectively). This correlation is
not as well de®ned for patients with plasma levels > 0.5 mg per ml.
Overall, the analysis suggests that although infections due to isolates
with itraconazole MIC > 0.25 mg per ml are less likely to respond
than those due to more susceptible organisms, the therapeutic effect
may be enhanced by ensuring that the plasma levels exceed 0.5 mg
per ml. It is worth mentioning that the data analyzed for
itraconazole are exclusively for patients with oropharyngeal
candidiasis.
Based on the analysis of the data packages discussed above, the
NCCLS proposed tentative breakpoints for antifungal susceptibility
testing of ¯uconazole and itraconazole. The breakpoints and the
conceptual framework followed to develop them are elegantly
presented by Rex et al (1997). Table I summarizes the breakpoints
to these agents. Interpretive breakpoints for 5-¯uorocytosine were
also proposed by the NCCLS Committee. As data similar to that of
¯uconazole and itraconazole were not available to the Committee,
the proposed breakpoints for 5-¯uorocytosine were based on
historical data. Finally, interpretive breakpoints for amphotericin B
were not put forward. This could be attributed primarily to the fact
that M27 methodology does not discriminate between susceptible
and resistant isolates. Thus, amphotericin B breakpoints must await
further studies that will allow such discrimination.
Now that the interpretive breakpoints have been in use for the
last 3 y, it is clear that physicians are using them with some degree
of success. This is evident by the recommendation of the Mycoses
Study Group to use antifungal susceptibility testing in the
management of patients with candidemia and acute hematogen-
ously disseminated candidiasis (Rex et al, 1995). Having said that, it
is important to put the predictive power of antifungal susceptibility
testing in perspective. Although good to excellent statistical
correlations have been shown between treatment success and
MIC values, physicians should consider other factors prior to
institution of treatment. Fungal infections are diseases of the
immunocompromised, and all too often underlying diseases and
other iatrogenic factors, unrelated to MIC, may be the deciding
factor in success or failure of a given treatment.
ANTIFUNGAL AGENTS IN CLINICAL USE
Polyenes Since its discovery in the 1950s, amphotericin B has
been the most widely used antifungal agent to treat invasive or life-
threatening fungal infections. Amphotericin B has fungicidal action
against microorganisms that contain sterols (ergosterol in particular)
in their outer cell membrane. The interaction of amphotericin B
with membrane sterol results in the production of aqueous pores
containing an annulus of eight amphotericin B molecules linked
hydrophobically to the membrane sterol (Holz, 1974). This
con®guration gives rise to a pore in which the polyene hydroxyl
residue faces inward, leading to altered permeability, leakage of vital
cytoplasmic components, and death of the organism (Kerridge,
1980). Despite the broad-spectrum of fungicidal activity,
amphotericin B has a narrow therapeutic index that limits its
clinical usefulness (Gallis et al, 1990). Fever, chills, nausea,
vomiting, headache, and electrolyte imbalance are common;
thrombocytopenia, generalized seizure, and shock are also
reported infrequently in patients treated with amphotericin B. In
children, overdose has been found to cause arrhythmia, cardiac
arrest, or even death (Cleary et al, 1993). The exact mechanism for
toxicity of amphotericin B is not clear, but nephrotoxicity may
arbitrarily be classi®ed as vascular or tubular, and the interference of
amphotericin B with mammalian membrane properties may
underlie all of the nephrotoxic effects (Sawaya et al, 1995).
Several strategies including combination therapy, modi®cation of
amphotericin B molecule and of the physical state of amphotericin
B, or changes in drug delivery system have been used to overcome
the toxic side-effects of amphotericin B (Hossain and Ghannoum,
2000). Incorporation of amphotericin B in lipid represents one such
approach. The lipid formulations of amphotericin B, complexed
with phospholipid or detergent, can modify the distribution of
amphotericin B in vivo, maintaining activity and lowering toxicity
(Brajtburg and Bolard, 1996).
Three types of lipid formulations of amphotericin B, namely
amphotericin B lipid complex (abelcet), amphotericin B colloidal
dispersion (amphotec), and liposomal amphotericin B (amBisome),
incorporated into sheet, disc, or liposome, respectively, are
available for clinical use. In the U.S.A., abelcet, amphotec, and
amBisome are being used for treating invasive fungal infections in
patients intolerant or refractory to conventional amphotericin B.
AmBisome is also being used for empiric treatment of febrile
neutropenic patients. The three lipid formulations are effective
against pathogenic fungi, and are less toxic than conventional
amphotericin B. Ef®cacy data available on the new products cover a
wide variety of systemic mycoses including candidiasis (Wong-
Beringer et al, 1998).
Azoles In view of the toxicity of amphotericin B and the
limited activity and development of resistance to ¯ucytosine,
discovery of the azoles in 1970s was considered a major therapeutic
breakthrough in antifungal chemotherapy. The approval of the
imidazoles and the triazoles (the N-substituted imidazoles) in
the late 1980s and the early 1990s was a major advancement in
safe and effective treatment of super®cial and deep fungal
infections. These compounds exert fungistatic effects by
inhibition of sterol biosynthesis. The primary target of azoles is
the heme protein, which cocatalyzes cytochrome P450-dependent
14a-demethylation of lanosterol (Hitchcock et al, 1990). Inhibition
of 14a-demethylase leads to the depletion of ergosterol, the
bioregulator of membrane ¯uidity and asymmetry, and to the
accumulation of sterol-precursors including 14a-methylated
Table I. Tentative interpretive guidelines for susceptibility testing in vitro of Candida species
Antifungal agent Susceptible (S) Susceptible-dose dependent (S-DD)a Resistant
Fluconazole < 8 16±32 > 64
Itraconazole < 0.125 0.25±0.5 > 1
5-¯uorocytosine < 4 8±16 > 16
aFor 5-¯uorocytosine, the old term ``intermediate susceptibility'' (I) is used instead of S-DD by the NCCLS Committee. Values are in mg per ml.
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sterols. These membranes fail to maintain optimum permeability
with a consequent loss of essential cytoplasmic material and
eventual cell death.
The clinical ef®cacy and safety of the second-generation azoles,
¯uconazole followed by itraconazole in particular, have had a
dramatic impact on the management of invasive fungal infections
caused by a wide variety of fungi, including yeasts, dermatophytes,
and to some extent molds. Itraconazole and ¯uconazole have
become frequently used therapeutic alternatives to amphotericin B
(Kauffman and Carver, 1997); however, with the widespread use,
resistance to azoles has emerged and become of some concern.
Candida albicans strains from AIDS patients with oropharyngeal
candidiasis often show resistance to ¯uconazole and, in some
strains, cross-resistance to itraconazole and ketoconazole (Laguna
et al, 1997). Prolonged itraconazole prophylaxis in AIDS patients
has also been found to result in reduced susceptibility to
itraconazole and cross-resistance to ¯uconazole (Goldman et al,
2000). Extensive studies on azole-resistance mechanisms in
C. albicans strains have been done. Of particular importance are
enhanced activity of cytochrome P450 14a-demethylase enzyme
(Vanden Bossche et al, 1994), energy-dependent ef¯ux pump
(Prasad et al, 1995), and decreased susceptibility to azoles (Lamb
et al, 1997). Various mechanisms have also been proposed for
resistance in C. glabrata strains, such as energy-dependent drug
ef¯ux (Miyazaki et al, 1998) and de®ciency of mitochondrial DNA
(Defontaine et al, 1999). Irrespective of the mechanisms involved in
azole-resistance there is a signi®cant impact on treatment outcome.
For a review of the mechanisms of antifungal resistance, the reader
is referred to the recent article by Ghannoum and Rice (1999).
Another potential limitation of the azole antifungal drugs (particu-
larly itraconazole) is the frequent drug interactions that result in
adverse clinical consequences, such as lowered potency of the azole
or toxicity of the coadministered drug (Hoesley and Dismukes,
1997).
Pyrimidine analog Antifungal activity of ¯ucytosine (5-
¯uorocytosine, 5-FC) was reported in the early 1960s, although
the only drug of the class was approved for use in humans in the
early 1970s. 5-FC is a ¯uorinated pyrimidine with inhibitory
activity against pathogenic fungi, including Candida species and
Cryptococcus neoformans. 5-FC enters the fungal cells aided by a
permease enzyme. Inside the cell, it is converted to 5-¯uorouracil
(5-FU) by the enzyme cytosine deaminase. Subsequently, 5-FU is
converted by UMP pyrophosphorylase into 5-¯uorouridylic acid,
which is further phosphorylated and incorporated into RNA,
resulting in disruption of protein synthesis (Polak and Scholer,
1975). 5-FU is also converted to 5-¯uorodeoxyuridine
monophosphate, a potent inhibitor of thymidine synthase, an
enzyme involved in DNA synthesis and nuclear division (Diasio et
al, 1978). Thus, 5-FC acts by interfering with pyrimidine
metabolism, as well as RNA, DNA, and protein synthesis in
fungal cells. The drug has a narrow spectrum of activity and 5-FC
monotherapy is not encouraged because of easy development of
resistance. Thus, it is usually administered in combination with
amphotericin B or ¯uconazole to treat systemic mycoses. In
addition to gastrointestinal upset including nausea, vomiting, and
anorexia, as well as bone marrow suppression, 5-FC may cause
impairment of renal function when administered with a
nephrotoxic drug such as amphotericin B. Thus, monitoring of
the serum level and rational dose adjustment may be needed for a
successful treatment outcome.
Newer antifungal agents
New formulation of polyene compounds Nystatin, the ®rst polyene
antifungal agent discovered in the 1950s, has been a well-known
drug for topical administration. Nystatin, being structurally related
to amphotericin B (tetraene macrolide), acts to some extent the same
way. Despite its fungicidal property, nystatin has not been developed
for treatment of systemic fungal infections because of its signi®cant
nephrotoxicity. Nystatin is an excellent drug for treatment of
super®cial Candida infections, but is not effective against
dermatophyte infections.
Liposomal nystatin, Nyotran, a liposomal formulation of nystatin
being developed by Aronex Pharmaceuticals, prepared by incorp-
oration of nystatin into multilamellar liposome, was found to retain
the in vitro antifungal activity of conventional nystatin and protect
human erythrocytes from lysis, suggesting lower toxicity.3,4 Unlike
the free nystatin that was toxic and lethal, liposomal nystatin at an
equivalent concentration was well tolerated. Improved survival of
mice and improved in vivo activity at higher doses prompted clinical
trials (Mehta et al, 1987). In a rabbit model of subacute disseminated
candidiasis, multilamellar liposomal nystatin was found to be less
nephrotoxic and had concentration-dependent activity comparable
with that of amphotericin B or ¯uconazole (Groll et al, 1999).
Nyotran is currently undergoing clinical trials.
Triazoles with extended spectrum of activity The
therapeutic success of ¯uconazole encouraged the development of
new triazole antifungal agents. The new third-generation azoles are
characterized by their broad spectrum activity and low toxicity.
The new triazoles share similar mechanisms of action as earlier
triazoles, and demonstrate potent antifungal activity against both
¯uconazole-susceptible and -resistant organisms. In this paper, a
brief discussion of three triazoles (voriconazole, posaconazole, and
ravuconazole) will be presented.
Voriconazole (UK-109 496), a triazole developed by P®zer, is
the most advanced in its preclinical and clinical evaluation.
Voriconazole is structurally related to ¯uconazole. It is available
in oral and intravenous formulations. Voriconazole was 8- to 130-
fold more active than ¯uconazole against Candida species sensitive
or resistant to ¯uconazole, including C. glabrata and C. krusei. It
appears to function by inhibiting fungal P450-dependent 14a-
demethylase enzyme, blocking sterol biosynthesis in a concentra-
tion-dependent manner (Belanger et al, 1997). Treatment of
¯uconazole-susceptible and -resistant C. albicans with voriconazole
completely blocked ergosterol synthesis and caused a signi®cant
increase in the level of squalene, 4,14-dimethylzymosterol, 24-
methylenedihydrolanosterol, and zymosterol. Accumulation of 24-
methylenedihydrolanosterol was observed in C. albicans and
C. krusei. Accumulation of the methylated sterols is consistent
with the premise that voriconazole inhibits fungal growth by
interfering with cytochrome P450-dependent 14-a-demethylase, a
known target enzyme for azoles. In a comparative study,
voriconazole showed potent in vitro concentration-dependent
antifungal activity, as well as more activity than ¯uconazole against
several clinical strains of C. glabrata (Koul et al, 1999). In another
study, voriconazole showed in vitro activity against both ¯ucona-
zole-susceptible and -resistant Candida species and was more potent
than itraconazole and ketoconazole (Nguyen and Yu, 1998).
Voriconazole was found to inhibit the growth and alter the
morphology of these candidal strains. Exposure of yeast to
voriconazole caused growth inhibition, cell wall thinning, and
cell membrane degradation (Sanati et al, 1997). Voriconazole was
more active than ¯uconazole in the inhibition of putative virulence
factors such as endothelial cell adherence, germination, and
endothelial cell injury by both ¯uconazole-resistant and ¯ucona-
zole-sensitive strains of C. albicans. It was also able to interfere with
endothelial cell damage by C. krusei (Fratti et al, 1998). Phase III
clinical trials with voriconazole have been completed.
3Wallace T, The Nyotran Study Group: In vitro antifungal activity of
nyotran against clinical isolates. Abstracts of the 14th Conference of the
International Society for Human and Animal Mycology. Buenos Aires, Argentina,
2000, abstr. 408
4Jessup C, Wallace T, Ghannoum MA: An in vitro interaction study with
Nyotran (liposomal Nystatin) and conventional antifungals, antibiotics,
antivirals, and immunosuppressive drugs against common fungal pathogens.
Abstracts of the 39th Interscience Conference on Antimicrobial Agents and
Chemotherapy. San Francisco: American Society for Microbiology, 1999,
abstr. 163
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Posaconazole (SCH 56592) is a new broad-spectrum triazole that
is being developed by Schering-Plough. Posaconazole is a
hydrogenated analog of itraconazole with a 1,3-dioxolone back-
bone. It is a potent inhibitor of lanosterol 14-a-demethylase and
has shown in vitro and in vivo activity against a variety of pathogenic
fungi, including Candida spp. (Law et al, 1997), C. neoformans
(Perfect et al, 1996), A. fumigatus (Oakley et al, 1997), B. dermatitidis
(Sugar and Liu, 1996), C. immitis (Lutz et al, 1997), and
H. capsulatum (Connolly et al, 1999). In a comparative in vitro
susceptibility study, posaconazole was more active than ¯uconazole
and slightly more active than either itraconazole or ketoconazole
against a large number of clinical yeast isolate (Barchiesi et al, 2000).
Ravuconazole (BMS-207147, formerly ER-30346) originally
discovered by Eisai (Japan), and licensed by Bristol-Myers Squibb,
is a new investigational triazole antifungal agent. Broad-spectrum
activity has been demonstrated for ravuconazole against various
pathogenic fungi (Fung-Tomc et al, 1998). A large-scale compara-
tive in vitro study showed ravuconazole was as active as
posaconazole or voriconazole against all clinical isolates of
Candida species, and more active than ¯uconazole and itraconazole;
however, ravuconazole, posaconazole, and itraconazole were more
active than ¯uconazole but less active than voriconazole against
C. glabrata (Pfaller et al, 1998a). MIC values of ravuconazole were
lower than those of itraconazole against Candida species, including
¯uconazole-resistant C. albicans, C. glabrata, and C. krusei. In
addition, ravuconazole was minimally affected by overexpression of
the gene encoding ef¯ux pump MDR1 (Fung-Tomc et al, 1999).
Antifungals targeting fungal cell wall Fungal cell walls are
composed of some unique components such as (1,3)-b-D-glucan,
mannan, and chitin. Unlike sterols, these components have no
mammalian counterpart. This uniqueness provides the advantage of
selective toxicity. Thus, polysaccharides are considered as novel
targets for antifungal therapy. The cell wall of most pathogenic
fungi, including C. albicans, is a multilayered structure, with its
outer layer composed of mannan, mannoprotein, and (1,6)-b-
glucan; the inner layer is composed predominantly of (1,3)-b-
glucan, chitin, and some mannoprotein (Surarit et al, 1988). (1,3)-
b-D-glucan is one of the essential structural components of fungal
cell walls, and has been used as a marker in serodiagnosis of invasive
fungal infection (Hossain et al, 1997; Yoshida et al, 1997).
Echinocandins and closely related pneumocandins are ampho-
philic lipopeptides that target (1,3)-b-D-glucan. These compounds
act by speci®c and noncompetitive inhibition of the (1,3)-b-D-
glucan synthase enzyme complex (which is essential for formation
of glucan polymers of the fungal cell wall), leading to depletion of
cell-wall glucan, osmotic instability, and lysis of fungal cell
(Debono and Gordee, 1994). Considering their novel mode of
action, these semisynthetic cyclic lipopeptides are being tested as
parenteral or oral agents for their antifungal potential. Of the three
groups of compounds (echinocandins, papulocandins, and aculea-
cin) that comprise the novel class of fungal lipopeptides, only
echinocandins have been extensively evaluated for their safety,
tolerability, and ef®cacy against C. albicans and other fungi. Unlike
cilofungin, an early echinocandin that was not developed because
of narrow spectrum of activity and nephrotoxicity, more improved
derivatives of echinocandins have been developed recently.
Caspofungin (MK-0991, formerly L 743872), being developed
by Merck, is a water-soluble antifungal with fungicidal activity
against yeasts in particular. Caspofungin has shown in vitro activity
against clinical isolates of ®lamentous fungi, including Aspergillus,
Fusarium, Rhizopus, and Pseudallescheria species (Pfaller et al, 1998b).
Caspofungin also showed in vitro activity against medically
important yeasts, and had low hemolytic potential (Bartizal et al,
1997). Caspofungin is undergoing phase II and III clinical trials.
FK 463 is an echinocandin-like compound developed by
Fujisawa. It is a water soluble, semisynthetic lipopeptide isolated
from the culture broth of Coleophoma empedri and is suitable for
intravenous use. It is a fungicidal agent, and is effective against
C. albicans, C. tropicalis, and C. glabrata and is more potent than
amphotericin B; however, it is fungistatic against Aspergillus species,
less active against C. krusei, C. parapsilosis, and C. guilliermondii, and
inactive against C. neoformans, Fusarium solani, Trichosporon asahii,
and T. cutaneum (Tawara et al, 2000). MIC of FK 463 were found
to be lower than those of several azoles and conventional
amphotericin B against azole-resistant CDR-expressed and
CaMDR-expressed C. albicans strains. In addition, in a murine
model of hematogenously disseminated candidiasis, FK 463 showed
ef®cacy against azole-resistant C. albicans strains that led to 100%
survival, signi®cant reduction of the tissue fungal burden, and the
lowering of the concentration of (1,3)-b-D-glucan in plasma. The
ef®cacy of FK 463 was superior to that of amphotericin B and
¯uconazole (Maesaki et al, 2000). Thus, FK 463 has a potential for
treatment of disseminated candidiasis caused by azole-resistant
strains.
MANAGEMENT OF CANDIDIASIS
As Candida causes a wide range of infections, ranging from nonlife-
threatening mucocutaneous infections to invasive processes that
may involve virtually any tissue, management of the different
clinical manifestations of candidiasis requires a broad range of
therapeutic and diagnostic strategies (Rex et al, 2000). These
strategies were recently addressed in two publications: (i)
``International Conference for the development of a consensus on
the management and prevention of severe candidal infections''
(Edwards et al, 1997) and (ii) ``Practical guidelines for the treatment
of candidiasis'' (Rex et al, 2000). For an in-depth coverage of this
issue, the reader should consult these two seminal articles. Both
documents stress that there is no one strategy to follow to manage
patients with candidiasis. In this regard, the choice of therapy
depends on the clinical status of the patient, the physician's
knowledge of the species, and the antifungal susceptibility of the
infecting isolate. The general strategy for the management of
candidemia and acute hematogenously disseminated candidiasis
entails that all patients be treated. It is recommended that patients
with candidemia be treated for 2 wk following the last positive
culture. Moreover, patients begun on amphotericin B may be
switched to ¯uconazole to complete the course of therapy. It is
imperative that all existing central venous catheters be removed.
Finally, it is critical that patients with suspected disseminated
candidiasis undergo ophthalmologic examination. Failure to do so
often has grave consequences such as loss of sight.
Relevant to practicing dermatologists, the practical guidelines
(Rex et al, 2000) propose strategies for the management of
nongenital mucocutaneous candidiasis. Although onychomycosis is
usually caused by dermatophytes (over 90% of cases), infections due
to C. albicans species also occur (between 0%±7% to 2%). Candida
onychomycosis responds to treatment with itraconazole (Roseeuw
and de Doncker, 1993; de Doncker et al, 1995). Recent data from
our group and others show that terbina®ne has in vitro activity
against a broad range of fungi, including yeast (Ryder et al, 1998;
Jessup et al, 2000b). Non-hematogenous primary skin candidal
infections are effectively treatable with topical azoles, polyenes, and
allylamines. Finally, systemic antifungal therapy with azoles is
ef®cacious for the treatment of chronic mucocutaneous candidiasis.
It is clear that Candida is an emerging pathogen that surfaced in
the last two decades as a result of advancements in modern
medicine and therapy. The epidemiology of this disease is
constantly changing in response to alterations of the host immune
status by, for example, HAART therapy. Moreover, the pattern of
Candida spp. causing disease is also dynamic and in¯uenced by the
introduction of newer antifungals. These changes are impacting the
way physicians manage patients with candidiasis.
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